Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Roisin Connolly, MBBCh
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Alabama Comprehensive Cancer Center
Birmingham, Alabama, United States
- Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital
Washington D.C., District of Columbia, United States
- Indiana University Simon Cancer Center
Indianapolis, Indiana, United States
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
- Vanderbilt University
Nashville, Tennessee, United States
- Baylor College of Medicine
Houston, Texas, United States
- the University of Texas Md Anderson Cancer Center
Houston, Texas, United States
- Fred Hutchinson Cancer Research Center - University of Washington
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jan 2014
- Primary completion
- 20 Mar 2018
- Completion
- 30 Jun 2027
- Last update posted
- 1 Jul 2026
- Registered enrollment
- 88
- Registry id
- NCT01937117
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.